JBC Papers in Press. Published on December 9, 2011 as Manuscript M111.287771
The latest version is at http://www.jbc.org/cgi/doi/10.1074/jbc.M111.287771

Genomic Promoter Occupancy of Runt-Related Transcription Factor RUNX2 in Osteosarcoma Cells Identifies Genes Involved in Cell Adhesion and Motility

Margaretha van der Deen[1], Jacqueline Akech[1], David Lapointe[2], Sneha Gupta[1], Daniel W. Young[1], Martin A. Montecino[3], Mario Galindo[4], Jane B. Lian[1], Janet L. Stein[1], Gary S. Stein[1], Andre J. van Wijnen[1]

From [1]Department of Cell Biology and Cancer Center, and
[2]Information Services Department,
University of Massachusetts Medical School, Worcester, MA 01655 USA

[3]Centro de Investigaciones Biomedicas, Facultad de Ciencias Biologicas y Facultad de Medicina, Universidad Andres Bello, Santiago, Chile

[4]Faculty of Medicine, Institute of Biomedical Sciences ICBM, University of Chile, Santiago, Chile.

Running Title: *Genomic function of RUNX2 in osteosarcoma cells*

To whom correspondence should be addressed: Andre J. van Wijnen and Gary S. Stein, Department of Cell Biology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655-0106. E-mails: andre.vanwijnen@umassmed.edu and gary.stein@umassmed.edu.
Submitting Author/Editorial Correspondence: Andre J. van Wijnen. Fax: 508-856-6800; E-mail: andre.vanwijnen@umassmed.edu.

Keywords: RUNX2, transcription, gene expression, osteosarcoma, cell motility, focal adhesion, FAK, PTK2, TLN1

Background: The osteogenic Runt-related (RUNX) transcription factor Runx2 is frequently elevated in osseous and non-osseous tumor cells.
Result: Genomic RUNX2 target genes were identified, and RUNX2 depletion reduces cell motility and adhesion in osteosarcoma cells.
Conclusion: RUNX2 regulates cell motility and adhesion in osteosarcoma cells.
Significance: RUNX2 may also control migration of normal osteoblasts and/or tumor cells.

SUMMARY

Runt-related transcription factors (RUNX1, RUNX2 and RUNX3) are key lineage-specific regulators of progenitor cell growth and differentiation, but also function pathologically as cancer genes that contribute to tumorigenesis. RUNX2 attenuates growth and stimulates maturation of osteoblasts during bone formation, but is also robustly expressed in a subset of osteosarcomas, as well as in metastatic breast and prostate tumors. To assess the biological function of RUNX2 in osteosarcoma cells, we examined human genomic promoter interactions for RUNX2 using chromatin immunoprecipitation (ChIP)-microarray analysis in SAOS-2 cells. Promoter binding of both RUNX2 and RNA Polymerase II (RNAPII) was compared with gene expression profiles of cells in which RUNX2 was depleted by RNA interference. The majority of RUNX2 bound loci (1550 of 2339 total) exhibit promoter occupancy by RNAPII and contain the RUNX consensus motif 5'[T/A/C]G[T/A/C]GG[T/G]. Gene ontology analysis indicates that RUNX2 controls components of multiple signaling pathways (e.g., WNT, TGFβ, TNFα, and interleukins), as well as genes linked to cell motility and adhesion (e.g., the focal adhesion related genes FAK/PTK2 and TLN1). Our results reveal that siRNA depletion of RUNX2, PTK2 or TLN1 diminishes motility of U2OS osteosarcoma cells. Thus, RUNX2 binding to diverse gene loci may support the biological properties of osteosarcoma cells.

Runt-related (RUNX) transcription factors have emerged as potent gene regulators that are associated with both tissue development and oncogenesis. RUNX proteins control cell fate by regulating cell growth and differentiation of progenitor cells in different lineages (1-3). Deregulation of the function or expression of these factors is causally linked to distinct cancer phenotypes (4-8). Null mutations in Runt-related transcription factors (RUNX1/ AML1, RUNX2/ CBFA1 and RUNX3/ PEBP2alphaC) cause major lineage-specific defects during mammalian development, while both loss- and gain-of-function mutations have been pathologically associated with cancer. For example, RUNX1 is frequently rearranged in Acute Myelogenous Leukemia (1,2), and null mutations in mice abolish definitive hematopoiesis during fetal development (9-11). Silencing of RUNX3 gene expression contributes to the etiology of carcinomas in multiple tissues (4,5), and loss-of-function mutations cause alterations in gastro-intestinal and neuronal tissues during post-natal development (12-14). Ectopic activation of RUNX2 upon retroviral integration contributes to T cell lymphomas in a Myc-dependent mouse model (15-18). Furthermore, genetic mutations in RUNX2 are linked to cleidocranial dysplasia in human patients (19-22). Mutations that abolish DNA binding and/or transcriptional functions, or mutations that generate dosage-insufficiency of RUNX2 in mouse models result in skeletal malformations at least in part due to a maturational arrest (23-26). Such RUNX2 mutations also result in growth deregulation in osteoblasts and embryonic fibroblasts (27-32). While RUNX3 is silenced during tumorigenesis, unscheduled expression of RUNX1 and RUNX2 has been observed in several major cancer types (e.g., breast and prostate) (1-8), indicating that the latter two proteins play active roles in tumor etiology.

Cell autonomous effects in tumors that exhibit altered RUNX function or expression are attributable to gene regulatory functions of RUNX proteins. RUNX2 is endogenously expressed during the cell cycle in normal osteoblasts and expressed at increased levels upon cessation of growth and subsequent maturation of osteoblasts (27,28,33). While RUNX2 is a natural suppressor of normal osteoblast proliferation, it is aberrantly expressed at elevated levels in a subset of cells derived from patients with osteosarcoma (OS), a pediatric disease that is prevalent in adolescent patients (34-37). The increased levels of RUNX2 suggests that its growth suppressive potential may be bypassed, thus permitting expression of its putative oncogenic functions in osteosarcoma. An extensive but incomplete catalogue of RUNX target genes expressed in osteoblasts, as well as in osteosarcoma, breast and prostate tumor cells, has emerged (7,31,38-52). These genes generally alter pathways linked to cell proliferation and survival, as well as other cellular activities required for tumorigenesis or cancer metastasis. However, a comprehensive assessment of gene regulatory networks controlled by RUNX proteins in specific tumors is necessary.

In this study, we have analyzed the genomic function of RUNX2 in osteosarcoma cells to gain insight into molecular pathways that are perturbed in bone cancer. We examined loci that are directly bound and controlled by RUNX2 using whole genome chromatin immuno-precipitations (ChIPs) for RUNX2 combined with genome-wide promoter microarrays (ChIP-on-chip), as well as gene expression profiling of cells depleted of RUNX2 using siRNAs. Our results reveal that RUNX2 controls genes and networks that are related to cell migration and adhesion, as well as other programs in osteosarcoma cells.

EXPERIMENTAL PROCEDURES

Chromatin immuno-precipitation (ChIP) assays

ChIP assays were performed with SAOS-2 cells that were grown in McCoy's medium (Thermo Scientific, Logan, UT) supplemented with 15% fetal bovine serum (FBS), penicillin/streptomycin and L-glutamine (all from Invitrogen/Gibco, Carlsbad, CA). SAOS-2 cells were grown to ~80% confluence and were cross-linked for 10 min in culture medium at room temperature with 1% formaldehyde solution. Fresh formaldehyde stock solution contained 50 mM HEPES-KOH, pH7.5, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, and 11% formaldehyde. Cross-linking was terminated by incubation of cells with 0.125 M glycine solution for 5 min. Cells were washed twice with 1× PBS, placed on ice and harvested using a cell scraper in PBS with protease inhibitors (Complete, Roche, Nutley, New Jersey). Cells were collected by

centrifugation at 4ºC, rapidly frozen in liquid nitrogen and stored at -80ºC. Cell pellets were thawed on ice before each use.

ChIP was performed using previously published protocols (53-55). In brief, cells were resuspended in Lysis Buffer #1 (50 mM HEPES-KOH, pH 7.5, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100, 1× protease inhibitors) for 10 min, collected by low speed centrifugation and resuspended in Lysis Buffer #2 (10 mM Tris-HCl, pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1× protease inhibitors) for 10 min at room temperature. After the second centrifugation step, pellets were resuspended in 3 ml of Lysis Buffer #3 (10 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% sodium deoxycholate, 0.5% *N*-lauroylsarcosine, 1× protease inhibitors), and chromatin was sonicated to an average length of ~500 bp. For SAOS-2 cells, sonication was optimized to 16 pulses of 30 s with intervals of 30 s using a Sonic Dismembrator (Model 550, Thermo Fisher Scientific, Waltham, Massachusetts), while samples were maintained on ice at 4ºC. Triton X-100 was added (300 µl) to the sonicated lysate, and cellular debris was removed by micro-centrifugation at 16,000g. Supernatants were adjusted with Sonication Buffer to the equivalent of ~$1.5x10^7$ cells per ChIP sample. Input genomic DNA was saved separately and stored at -20ºC until further use.

Dynal beads (Protein G, 100 µl/ChIP, Invitrogen, Carlsbad, CA) were washed with blocking solution (PBS/0.5% BSA, filtered) and pre-coated overnight with anti-RUNX2 antibodies (M70, 12 µg, Santa Cruz Biotechnology, CA), Polymerase II antibody (8WG16, 10 µl, Covance, Princeton, NJ) or IgG (rabbit polyclonal, 12 µg, Santa Cruz) as a negative control. After three washes with blocking solution, 1 ml of chromatin was added and suspensions were rotated for a minimum of 8 h at 4ºC. Beads were collected by magnetic attraction using a Magnarack (Invitrogen) and resuspended in 1 ml of RIPA buffer (50 mM HEPES-KOH, pH 7.5, 500 mM LiCl, 1 mM EDTA, 1.0% NP-40, 0.7% sodium deoxycholate). This rinse cycle was repeated five times. Samples were then subjected to a single wash with 1 ml TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA) and recovered by low-speed centrifugation at 900 g for 3 min. Beads were resuspended in 210 µl elution buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 1.0% SDS) and incubated at 65ºC for 25 min with intermittent agitation (vortex) at ~2 min intervals to elute chromatin. Beads were recovered by centrifugation for 1 min at 16,000g at room temperature, and 200 µl was transferred to a new 1.5 ml tube. At this step, 20µl (2%) of the input sample was diluted with 180 µl of elution buffer and processed in parallel with the ChIP samples.

Cross-linking was reversed by incubating the suspensions for 12 h at 65ºC in an oven. The next day, samples were incubated for 2 h at 37ºC in the presence of RNaseA (0.2 mg/ml in 200 µl TE buffer) and subsequently for an additional 2 h at 55ºC in the presence of Proteinase K (0.2 mg/ml). DNA was purified using phenol:chloroform:isoamyl alcohol (USB, Cleveland, OH) extraction with phase-separation in Heavy Phaselock tubes (Eppendorf, Hamburg, Germany) followed by DNA precipitation with ethanol using standard procedures. DNA pellets were resuspended in 20 µl 10 mM Tris-HCl, pH 8.0 and DNA concentrations of input samples were measured using a Nanodrop instrument (Thermo Fisher Scientific)(note: DNA concentrations of ChIP samples are below the level of detection). The DNA size range and efficiency of DNA fragmentation was evaluated by ethidium bromide staining of input samples using a 1.5% agarose gel (average DNA fragment size ~500 bp).

DNA was amplified by adapting the standard protocol for whole genome amplification (WGA) using the GenomePlex WGA2 kit (Sigma) as described previously (55). Briefly, the initial random fragmentation step was eliminated and DNA from 10 µl of ChIP sample or from 10 ng of input chromatin was amplified using 22 PCR cycles. DNA was purified using the Qiaquick PCR purification kit (Qiagen Sciences, Beverly, Massachusetts) and resuspended in 30 µl of nuclease-free water. Final DNA concentrations were measured using the Nanodrop device. ChIP DNA was analyzed with quantitative PCR using positive and negative controls, both before and after WGA amplification. ChIP enrichment was determined using a 7300 sequence detection system (Applied Biosystems, Foster City, CA) with SYBR Green chemistry. The ChIP signal was normalized to the input sample and total DNA

content. ChIP qPCR primers were designed in the peak regions of human gene promoters, preferably around genomic locations where potential RUNX2 binding elements were located (sequences for the ChIP PCR primers are summarized in **Supplementary Table S1**). Only samples that met stringent quality criteria based on multiple positive and negative controls (e.g., expected immuno-precipitation and amplification of known RUNX2 responsive genes but not unrelated genes based on ChIP-qPCR; uniform WGA amplification of different genomic segments) were submitted for Nimblegen ChIP-on-chip analysis (Roche NimbleGen Inc., Madison, WI).

ChIP-on-chip assays

Amplicons were labeled with Cy5 (ChIP sample), and Cy3 (input sample) by Roche Nimblegen and hybridized to human HG18 Refseq promoter arrays, that cover on average 2200 bp upstream and 500 bp downstream with a median probe spacing of 100 bp (see www.nimblegen.com for details). In brief, raw data of the fluorescence intensities were obtained from scanned images of the oligonucleotide tiling arrays using NimbleScan 2.3 extraction software (Nimblegen Systems). For each spot on the array, log2 ratios of the Cy5-labeled test sample versus the Cy3-labeled reference (input) sample were calculated. The biweight mean of this log2 ratio was subtracted from each datapoint. Peak search analysis was performed with NimbleScan 2.3 software, and log2 ratios and false discovery rates (FDR) were calculated for every peak (**Supplementary Table S2**).

The ChIP-chip samples were validated using several control experiments. First, we examined the enrichment on the arrays of selected positive and negative control promoters by ChIP-qPCR before and after whole genome amplification to ensure that the positive controls were enriched and that negative controls were not enriched. Second, we performed arrays using two independent ChIP samples which revealed the reproducibility of the data sets. Third, the overlapping peak regions for different ChIP samples were visually inspected and found to be very reproducible in biological replicates. Fourth, a subset of targets identified on the arrays was validated using ChIP-qPCR assays with primers near RUNX motifs in peak regions or outside peak regions (negative controls).

Motif analysis

Peak regions that were consistently positive (i.e., exhibiting peak overlap) in duplicate ChIP-on-chip experiments were analyzed in both the sense and anti-sense directions for the occurrence of the RUNX consensus motif 5'[T/A/C]G[C/T]GGT or the related variant RUNX motifs 5'TGTGGG and 5'TGAGGT that are known to bind RUNX2 in vitro (29,56). Motif searches were conducted within a 500 bp sequence centered on the region of peak overlap (i.e., 250 bp on each side) in duplicate experiments (**Supplementary Table S3**). Aligned peak regions were also examined for co-regulatory elements in the vicinity of RUNX motifs using Clover (http://cagt.bu.edu/page/Clover), JASPAR, and TRANSFAC databases (57-61) but these analyses did not yield definitive evidence of co-motif enrichment.

RNA interference

Osteosarcoma cells (SAOS-2 or U2OS) were seeded in six-well plates and transfected the next day at 30-40% confluency with different oligonucleotides using Oligofectamine™ Reagent (Invitrogen) in 1 ml Opti-MEM (a reduced serum medium from Invitrogen) according to the manufacturer's instructions. After 4 h, 0.5 ml fresh culture medium containing 3x concentrated FBS was added. Cells were harvested 48 h (Western blot or qPCR) or 72 h (gene expression profiling) after transfection (40).

For gene expression profiling, three different small interfering RNA duplexes directed against human RUNX2 (siRUNX2) mRNA were purchased from Qiagen, indicated as siRUNX2 #A, #B, and #C. The target sequences were as follows: siRUNX2#A: 5'-CTC TGC ACC AAG TCC TTT T dTT-3'; siRUNX2#B: 5'-AAT GCC TCT GCT GTT ATG AAA-3', and siRUNX2#C: 5'- AAG GTT CAA CGA TCT GAG ATT-3'), and oligonucleotides were used at 50 nM. Control cells were transfected with siRNA duplexes specific for CAT, GFP or non-silencing siRNA (Qiagen, Inc.) using the same concentrations and vehicle alone as control (40).

For western blots and RT-qPCR validation studies, siRUNX2#B and #C oligos were used, or

siRUNX2 oligos from Dharmacon (on-target plus smartpool J-012665-00). Control cells were treated with non-silencing (siNS) oligos from Qiagen (target sequence 5'-AAT TCT CCG AAC GTG TCA CGT-3') or Dharmacon (on-target plus siControl non-targeting pool D-001810-10).

Gene expression profiling and analysis

Affymetrix microarray analyses (Hu-U133Plus2 chips) were performed using RNA samples isolated from asynchronous SAOS-2 cells that were treated with RUNX2 siRNA and non-silencing siRNAs. RNA samples were processed essentially as described previously (40,62,63). Signals from each microarray were analyzed, normalized, and converted to a numerical output using the Affymetrix GeneChip software. The data generated by the different arrays were globally scaled to an average intensity of 1500. The average expression value for each gene across the arrays was used to normalize the mRNA intensities. Adjusted data were subjected to further analysis using Xcluster (63,64).

Gene expression values from the arrays were calculated from raw CEL data using the method of Li and Wong (62). Raw data from the Hu-U133Plus2 chips were normalized and processed using dChip. Low and negative values were truncated upward to a uniform value of 150 and genes that had at least one *P* designation were used for further analysis. For a given gene, the mean expression value x_t (log units) for three independent siRNA experiments for RUNX2 (oligos #A, #B, and #C) was compared with the mean gene expression x_c (log units) of the three non-silencing negative controls (siCAT, siGFP and siNS) using a cumulative distribution function, where *s* is the SD (log units) of the samples (19). A t-test was applied for comparisons, and a *P*-value ≤ 0.05 was considered significant. Because RUNX2 oligo #C is much more efficient than #A and #B, we also performed a z-test in which oligo #C was compared with the three non-silencing oligos to identify genes that are modulated when cells are most depleted of RUNX2 (**Supplementary Table S4**).

RNA extraction and real-time quantitative PCR

Total RNA was purified using Trizol (Invitrogen) and subjected to DNase I digestion prior to cDNA preparation using the qScript cDNA synthesis kit (Quanta). Relative quantification of amplified DNA was determined using a 7300 sequence detection system (Applied Biosystems/Roche, Branchburg NJ). Gene expression was monitored using real-time primer pairs with SYBR Green detection (Applied Biosystems) (see **Supplementary Table S1**), except for RUNX1 primers which used a Taqman probe for detection (Applied Biosystems; catalog number Hs00231079_m1). The relative mRNA expression was calculated with the ΔΔCT method. All primers used in the study were very carefully selected for maximal amplification efficiency (>90%) and all dissociation curves displayed one single peak. For qPCR array analysis, multiple genes (>50 genes with 2 primer pairs each) were analyzed with the linear regression method (LinRegPCR quantitative PCR data analysis program, http://LinRegPCR.HFRC.nl (version 11.0) (65).

Western blot analysis

Cells were lysed in RIPA buffer (Boston Bioproducts) and 2xSDS sample buffer supplemented with protease inhibitors (Complete, EDTA-free, Roche Diagnostics, Mannheim, Germany) and MG132 (Calbiochem). Lysates were fractionated in a 10% acrylamide gel and subjected to immunoblotting (BioRad system). Immunoblots were incubated for one hour with the following primary antibodies: RUNX2 (mouse monoclonal, MBL), or anti-CDK2 (clone M2, Santa Cruz). Peroxidase labeled goat-anti-rabbit or goat-anti-mouse secondary antibodies (Santa Cruz) were used to visualize bands with enhanced chemiluminescence (ECL) chemistry (PerkinElmer, Waltham, MA) on BioMax film (Kodak).

Migration and Invasion assay

U2OS human osteosarcoma cells were depleted of RUNX2 using siRNAs as described above. At 48 h after transfection, cells were harvested using trypsin and counted in medium containing FBS. Cells were washed once with growth medium without supplements, collected by centrifugation and resuspended with medium containing 0.1% BSA (Fraction V, Sigma).

In vitro wound healing assays were carried out with U2OS cells that were pre-treated with siRNAs for RUNX2 or representative RUNX2

targets associated with cell migration. Cells were grown until 80% confluence and scratched with a 200 µl pipette tip to create a cell free area ('wound')'. Cells were washed to remove unattached cells and incubated for 24 h and examined by light microscopy. Three fields for each treatment in three independent experiments were imaged and quantified using ImageJ.

For trans-well assays, the cell concentration was adjusted to 5 x 10^4 cell/ml, and the cell suspension was introduced into Matrigel invasion chambers or control plates without Matrigel (BD Biosciences, Bedford, MA). Before seeding, Matrigel plates were rehydrated for 2 h with warm incomplete medium at 37ºC and normal growth medium containing FBS (0.75 ml) was added to the lower wells. Cells were incubated for 24 h to permit migration and invasion, and cells were removed from the upper membrane surface using cotton-tipped swabs. Cells that migrated to the lower surface of the membrane were fixed and stained with the Hema-3 stain set (Fisher Scientific, Kalamazoo, MI). Hematoxylin and Eosin stained cells were photographed and counted. For each experimental condition, we calculated the average of 4 fields per well to cover nearly the entire well.

RESULTS

Genome-wide occupancy of RUNX2 at gene loci in osteosarcoma cells.

We performed two independent biological replicates of ChIP-on-chip experiments for RUNX2 in SAOS-2 human osteosarcoma cells that express high levels of RUNX2, compared to U2OS cells and normal osteoblastic cells, thus facilitating technical execution. We also carried out RNA Polymerase II (RNAPII) ChIPs to distinguish between genes that are being (or poised to be) transcribed and those that are not transcribed. For each sample, we initially examined RUNX2 and RNAPII binding to the RUNX2 promoter, which is known to be auto-regulated (66). The average enrichment of the two independent samples as determined by ChIP-qPCR was ~7-8 fold for RUNX2 antibodies and ~300 fold for RNAPII compared to the IgG controls **(Fig. 1A)**, thus pre-validating our samples for genome-wide ChIP analysis.

Duplicate ChIP-on-chip experiments with NimbleGen promoter tiling arrays revealed 2265 reproducible peaks for RUNX2 binding that are located adjacent to 2339 unique genes **(Fig. 1B and Supplementary Table S2)**. Of these genes, 1550 were also occupied by RNAPII (**Fig. 1B**). Corroborating the pre-validation assays, we find that the RUNX2 P1 promoter itself and the established RUNX2 target gene MMP13 are both occupied in duplicate arrays **(Fig. 2A)**. However, no RUNX2 binding is observed for the osteocalcin (BGLAP) gene, a classical RUNX2 target that is not expressed in SAOS-2 cells as reviewed by Rodan and Noda (67). Our analyses revealed many new potential target genes such as Talin 1 (TLN1) and cAMP responsive element binding protein 3 (CREB3) that are controlled by a shared intergenic regulatory region **(Fig. 2A)**.

Post-validation of the ChIP-on-chip results using qPCR, ChIP DNA was analyzed for enrichment of RUNX2 bound promoter segments (**Fig. 2B)**. As negative controls, we used primers that amplify genomic DNA adjacent to RUNX2 binding regions ('peaks') and exhibit negligible occupancy in NimbleGen arrays (data not shown). As a positive control, binding of RUNX2 to the RUNX2 P1 promoter on the arrays was post-validated by qPCR analysis (**Figs. 2A and 2B)**. A number of genes exhibiting robust RUNX2 binding were further characterized by qPCR analysis and represent novel targets, including RUNX1, PTK2, C10orf4 and SERPINE1, as well as the SCT-MUCDHL and TLN1-CREB3 gene pairs. Identification of RUNX1 as a RUNX2 target is consistent with functional cross-regulation between these related transcription factors in other biological contexts (unpublished observations). SCT and CREB3 are both linked to cell signaling, while MUCDHL, SERPINE1, TLN1 and PTK2 are all linked to cell adhesion and/or migration (see below). C10orf4 is an anonymous gene that is not well characterized. Our results suggest that ~9-10% of genes in the human genome (i.e., ~25,000 genes present on the array) may be controlled by RUNX2 in osteosarcoma cells, while RUNX2 is bound to ~23% of all genes that are associated with RNAPII (n=6,659 genes) **(Fig. 1B)**. Furthermore, binding of RUNX2 to genes, whether or not they are co-occupied by RNAPII, is consistent with the bi-functional role of RUNX2 in gene activation and suppression.

Genome-wide analyses of RUNX2 recognition motifs and co-regulatory elements

The recognition motif of Runt-related transcription factors was previously established by binding site selection for RUNX1/AML1 (68,69). We performed motif analysis to refine this recognition element and to establish its relative location at a genome-wide level as it occurs within the first 2 kilobases (kb) of selected target genes (i.e., the promoter segments that are represented on the NimbleGen arrays). We analyzed the distribution of RUNX2 binding in all 2,265 peak regions that were adjacent to 2,339 genes, relative to the transcription start site (TSS) and relative to RNAPII binding. RNAPII is concentrated near the TSS as expected. RUNX2 generally binds distal to RNAPII at ~800 bp upstream of the TSS, but RUNX2 binding is also enriched at ~300 bp downstream of the TSS **(Fig. 3A)**.

We addressed whether RUNX2 binding motifs are enriched in promoters with RUNX2 occupancy by assessing the presence of the consensus RUNX motif 5'[T/A/C]G[C/T]GGT (68) in peak regions. Motif analysis was performed using peak regions that overlap in duplicate experiments (i.e., alignment of a minimum of one tile). We found that ~83% of all overlapping peak regions contained RUNX motifs within 250 bp from the region of overlap, and 65% of these motifs were located within the region of peak overlap **(Figs. 3B and 3C)**. The motifs 5'TGTGGT and 5'AGTGGT, which are a perfect match with the consensus, were present with the highest and fourth highest frequency, respectively **(Fig. 3D)**. Interestingly, the one-mismatch motifs 5'TGTGGG and 5'TGAGGT, which are known to bind RUNX2 based on in vitro protein/DNA interaction assays (29,56), were the second and third most frequent, while the motif 5'CGCGGT was the least frequent. Our analysis establishes a consensus motif (5'[T/A/C]G[T/A/C]GG[T/G]) in which the subsequence [T/A]G[T/A]GG[T/G] accounts for the four most prevalent RUNX2 binding elements that together encompass 80-90% of all empirically determined binding sites **(Fig. 3D)**. The genome-wide RUNX2 consensus motif is in good agreement with the RUNX1/AML1 motif established by binding site selection (68), consistent with the high evolutionary conservation of the Runt-homology DNA binding domain.

Most peak regions (>80%) encompass one to five copies of this genome-wide RUNX2 consensus motif. A limited number of gene promoters (~24) contain a larger number of RUNX motifs (≥12) (e.g., NALP4, DRD1IP, DPCR1, RUNX1, ARSA, TRIM28, LTBP1, and HCCS) **(Supplementary Table S3)**. For example, the promoter for the NALP4 gene contains ~81 RUNX motifs near the peak region. This gene and others that contain many RUNX motifs in their promoters (e.g., NALP4, DPCR1, and MMEL1) are RNAPII negative. However, there is no clear correlation between the number of motifs and transcriptional status (i.e., whether a gene is activated or repressed by RUNX2 as inferred from RNAPII binding) **(Supplementary Figure S1)**.

Pathway analysis for RUNX2 target genes

To identify RUNX2 dependent regulatory networks that support its postulated pathological activity in osteosarcoma cells, we carried out gene ontology analysis using GeneSpring, Ingenuity and David 2.0 annotation programs (70). Target genes that exhibit the most robust binding in ChIP-on-chip analyses (i.e., genes with highest average log2 ratios; n = 1,000) were selected for these analyses. Based on GeneSpring analysis, RUNX2 occupies genes that support cell signaling by a number of extra-cellular ligands (e.g., Wnt, TNFα, TGFβ, EGFR, Notch, Hedgehog and A6B4 integrin) **(Supplementary Table S4)**. A6B4 integrin and TGFBR are of particular interest because these pathways are linked to cell adhesion and SMAD signaling, respectively, which are both mechanistically associated with the biological functions of RUNX2 (3) **(Supplementary Figure S2)**. Ingenuity pathway analysis (IPA) revealed that RUNX2 controls networks related to general cellular functions (e.g., protein synthesis, cellular assembly and organization, cell morphology, as well as molecular transport and amino acid metabolism) **(Supplementary Table S5)**. Furthermore, RUNX2 target genes are associated with, for example, endocrine disorders, immunological diseases, cancer, cell cycle, cellular movement, tumor morphology, and embryonic development. DAVID 2.0 analysis identified a large number of zinc-ion binding proteins (e.g., zinc finger transcription factors), as well as other transcription factors (e.g., ETS-related proteins) and co-regulatory factors (e.g.,

SMAD4 and WW domain proteins) **(Supplementary Table S6)**. Taken together, these analyses indicate that RUNX2 controls multiple distinct cellular functions in osteosarcoma cells.

Genome-wide responsiveness of target genes to modulation by RUNX2 siRNA

To understand which genes are most responsive to modulations in Runx2 levels, we determined expression values of genes using Affymetrix cDNA micro-array profiling in actively proliferating SAOS-2 cells that were treated with or without siRUNX2. SAOS-2 cells were treated with three distinct siRNAs for RUNX2 and three non-silencing oligos. Analysis of these triplicate data-sets identified ~140 genes that exhibit statistically significant changes in expression ($P<0.05$) and ~80 genes that trended towards significance ($0.05<P<0.07$) by the Student's t-test **(Supplementary Table S7 and data not shown)**. Differences in the efficacies of the three siRNAs in reducing RUNX2 levels generate statistical variation that prevents positive identification of responsive target genes. Therefore, we also determined gene expression values for the most effective siRunx2 oligo compared to the results for the three non-silencing oligos. This analysis identified ~488 genes that are modulated by 2 fold (statistical significance determined using a Z-test) **(Supplementary Table S8)**.

We compared genes directly bound by RUNX2 (identified by ChIP-on-chip analysis) with genes that display changes in expression upon RUNX2 depletion. The inherent difficulty of this comparison is that genes that are most tightly bound are least responsive to modest reductions in RUNX2 levels (see Discussion). Indeed, of the ~220 genes that responded to changes in RUNX2 gene expression (using a t-test), only 25 genes were also identified by RUNX2 promoter binding. Just 10 of these genes exhibit a greater than 1.4 fold change in expression upon RUNX2 depletion, beyond RUNX2 itself (see below). Similarly, of the ~488 genes that change by 2 fold (using a Z-test) **(Supplementary Table S8)**, only 67 were also discovered by ChIP-on-chip analysis (data not shown). The low representation of genes that are robustly modulated based on expression profiling and also detected by ChIP-on-chip analysis indicates that direct identification of RUNX2 targets by ChIP-on-chip does not necessarily predict responsiveness of genes to modulation of RUNX2 levels by siRNA knockdown (see Discussion).

Of the 10 genes that are modulated >1.4 fold respond to siRUNX2 depletion and exhibit promoter occupancy by RUNX2, two genes exhibit decreased expression: the planar cell polarity related gene PRICKLE1 and the RNA Polymerase III regulatory factor SNAPC1 **(Supplementary Table S9)**. The expression of a third RUNX2 bound gene, TGFBR2, also increases with siRUNX2 but this gene does not associate with RNAPII (i.e. in untreated control cells). This result suggests that TGFBR2 may be both directly and indirectly controlled by RUNX2. We identified 5 genes that are negatively regulated by RUNX2, based on clearly increased expression (>1.7 fold) with siRUNX2. Of these, 3 genes are transcribed or poised for transcription and suppressed by RUNX2 based on presence of both RUNX2 and RNAPII (i.e., RUNX1, RBBP4, COL5A1). Regulation of RUNX1 by RUNX2 reflects cross-regulation that complements auto-regulatory mechanisms for RUNX genes (66). RBBP4 interacts with the RUNX2 binding proteins pRB and HDAC3, which are both linked to gene repression (71), suggesting that RUNX2 participates in intricate transcriptional inhibitory networks. Two Runx2-bound genes (i.e., IGFS4, PSCD2) do not associate with RNAPII and are thus transcriptionally inactive, perhaps due to active repression by RUNX2. We conclude that RUNX2 interacts with genes that are actively transcribed or poised for transcription in osteosarcoma cells, as well as silent genes.

RUNX2 regulates genes involved in cell adhesion and motility in osteosarcoma cells and breast cancer cells

Many genes that strongly interact with RUNX2 have functions in cell motility and/or adhesion (**Figs. 4 to 6**). For example, two prominent target genes (i.e., appearing in the top of **Supplementary Table S2**) are related to focal adhesion kinase (FAK) function, i.e. FAK/PTK2 and Talin 1 (TLN1). We first examined these two genes and other representative targets by RT-qPCR analysis using mRNA isolated from cells treated with or without siRUNX2. We used SAOS-2 and U2OS osteosarcoma cells, which

express endogenous RUNX2, as well as MDA-MB-231 breast cancer cells that ectopically express RUNX2 (47).

Control experiments yielded the desired result that RUNX2 mRNA and protein were each significantly downregulated with two distinct siRNA oligos in all three cell lines (~40-60% mRNA and >70% protein) **(Fig. 4)**. Using RT-qPCR, we also validated several genes that are related to the FAK pathway (NEXN, TPM1, SHC1), as well as other genes that play a role in migration/adhesion targets by RT-qPCR validation **(Figs. 4 and 5)**. The expression of several motility-related genes (e.g., COL11A1 and FLRT2) is increased by more than 30% in response to siRUNX2 in SAOS-2 cells, suggesting that these genes are normally repressed by RUNX2. In MDA-MB-231 cells, the response of these same genes to siRUNX2 was more modest **(Fig. 4)**. Five genes that exhibit altered expression in RT-qPCR arrays upon RUNX2 depletion (PCDH18, PANX3, SVIL, COL24A1, ISL1) exhibit clear RUNX2 occupancy in duplicate ChIP-on-chip experiments **(Fig. 5)**.

ChIP-on-chip analysis identified a number of proteins associated with the FAK pathway (for example, PTK2, TLN1, NEXN, TPM1, SHC1). This finding suggests that RUNX2 controls cellular functions linked to motility and adhesion. PTK2 and TLN1 are among the ten most prominent RUNX2 target genes (by peak ratio), and both PTK2 and TLN1 are bound by RNAPII (**Fig. 2, Supplementary Table S2** and data not shown). PTK and TLN1 are functionally related genes that form a complex at focal adhesions to connect integrins with the actin cytoskeleton **(Fig. 6A)** (72,73). Therefore, these two proteins are in principle very attractive candidate target genes that may contribute to the predicted role of RUNX2 in cell adhesion and motility in osteosarcoma cells.

In testing this hypothesis, we encountered two major technical obstacles. First, standard SAOS2 cells are neither motile nor invasive (**Supplementary Figure S3** and data not shown). Hence, RUNX2 binding to components of the FAK pathway (e.g., TLN1 and PTK2) is not sufficient to generate a mobile cell. Therefore, we we investigated the function of RUNX2, and its targets PTK2 and TLN1 in U2OS cells which are intrinsically capable of migrating in cell culture.

Second, RUNX2 depletion in SAOS-2, U2OS or MDA-MB-231 cells has modest if any effects on TLN1 or PTK2 as established by RT-qPCR (**Fig. 4**). Also, neither TLN1 nor PTK2 was discovered as a Runx2 responsive gene by Affymetrix profiling using SAOS2 cells (see **Supplementary Tables S7 and S8**). Because of the lack of effects on the respective mRNAs, RUNX2 depletion is not likely to change the protein levels of either TLN1 or PTK2. Therefore, we tested the functions of these two RUNX2 targets directly using siRNAs for PTK2 and TLN1 in U2OS cells in parallel with studies using siRNA for RUNX2.

Cell motility studies were performed with in vitro wound healing ('scratch') assays and trans-well systems (**Figs. 6B, 6C 6D and 6E**). RUNX2 siRNA only reduces RUNX2 mRNA by 60% (**Fig. 6B**), but RUNX2 protein is decreased to barely detectable levels as determined by immunoblot analysis (**Fig. 6E**). Thus, we have obtained a robust knock-down of Runx2 that is expected to achieve a biological effect.

Cell motility is strongly reduced upon RUNX2 depletion, and to a lesser extent upon depletion of either TLN1 or PTK2 using siRNAs **(Figs. 6B, 6C and 6D)**. Furthermore, studies that monitor migration through Matrigel revealed that RUNX2 depletion results in considerable inhibition of U2OS cell invasion (**Fig. 6E**). The latter experiments were carried out with two different RUNX2 siRNAs. We obtained consistent results thus ruling out siRNA off-target effects. The combined results obtained with siRUNX2, siPTK2 and siTLN1 (**Fig. 6**) corroborate the generalized concept that RUNX2 regulates motility and is bound to a broad spectrum of motility-related genes. However, because RUNX2 depletion does not appreciably change PTK2 or TLN1 expression, these two genes cannot account for the observed siRUNX2 dependent changes in cell motility. We propose that other key target genes that are less tightly bound by RUNX2 may become rate-limiting for cell motility when RUNX2 gene expression is inhibited.

DISCUSSION

Aberrant expression of RUNX proteins has been linked to pathological events in cancer

cells. For example, increased expression of RUNX2 is observed in both osseous (e.g., osteosarcoma) and non-osseous cancers (e.g., breast and prostate) (7,8,34-36), indicating that RUNX2 may have an oncogenic function in tumor etiology. In this study, we have examined physiological targets of RUNX2 in osteosarcoma cells where the protein is endogenously over-expressed relative to normal osteoblastic cells. We analyzed genome-wide interactions of RUNX2 and RNAPII with gene promoters and also performed gene expression profiling in cells depleted of RUNX2. One key finding is that RUNX2 is bound to a large number (>2,000) of genes that are either actively transcribed or poised for expression (~60-70%) based on co-interactions of the same genes with RNAPII. RUNX2 also interacts with genes that appear to be inactive (~30-40%) as reflected by absence of RNAPII. The global observation that RUNX2 binds to both active and inactive genes in osteosarcoma cells is consistent with the general concept that RUNX2 is a bi-functional regulator that can activate or repress gene transcription depending on promoter context and cellular milieu.

Previous studies with osteogenic and osteosarcoma cells, as well as breast and prostate tumor cells, have identified a number of individual genes that respond to changes in RUNX2 protein levels (7,31,38-52). For example, in breast cancer cells, RUNX2 controls MMPs (e.g., MMP-9 and MMP-13) and VEGF that may be pathologically linked to key steps in cancer metastasis (74). However, few of the previously identified RUNX2 target genes characterized in different cell types appear to be controlled by RUNX2 in SAOS-2 osteosarcoma cells. Thus, the RUNX2 target genes identified in this study represent a distinct cell-context dependent subset of the total cohort of RUNX2 target genes.

Pathway analysis of RUNX2 target genes indicates that RUNX2 controls multiple regulatory networks. As expected from its well-known role as a regulator of osteoblast growth and differentiation, RUNX2 regulates genes that support bone cell growth and survival, as well as lineage commitment and differentiation (i.e., WNT-, TFGbeta-, TNFalpha-, EGF-signaling). However, the most interesting discovery of this study is that RUNX2 also controls pathways that are broadly related to cell adhesion and motility. Our results establish that depletion of RUNX2, or the RUNX2 target genes TLN1 or PTK2 decreases motility of U2OS cells. We note that these genes do not affect motility of SAOS-2 cells, because these cells are relatively immobile. Our finding that RUNX2 may have functions in cell adhesion and motility of mobile osteosarcoma cells complements earlier findings obtained with both loss-of function and gain-of-function experiments in murine models (e.g., Runx2 null mouse embryonic fibroblasts and murine T cell lymphoma cells (14-18)), as well as human breast and prostate cancer cells (45-47,75-78).

Our study combined ChIP data with gene expression profiling results of SAOS-2 cells treated with RUNX2 siRNA. The results revealed sets of RUNX2 target genes that are either down- or up-regulated by RUNX2 depletion, corroborating the bi-functional role of RUNX2 in gene regulation in osteosarcoma cells. Triplicate Affymetrix gene expression experiments with siRUNX2 treated cells identified multiple genes (between ~200 and ~1000) that were significantly modulated (>1.4 fold), but only a small subset (<20) of these genes were also occupied by RUNX2. We also observed that a number of RUNX2 bound genes are not responsive to RUNX2 depletion, although RUNX2 occupancy is clearly and reproducibly evident in separate experiments. The observation that tightly bound target genes are not necessarily most responsive to modulations in RUNX2 levels may have several molecular explanations (reviewed in (79)). For example, reduction of RUNX2 levels is more likely to affect genes to which RUNX2 binds with low affinity, because RUNX2 may only vacate high affinity genes upon complete loss of RUNX2 expression.

Two of the more fascinating genes controlled by RUNX2 are the focal adhesion kinase PTK2/FAK and TLN1. Both proteins are part of a complex that connects integrins with the actin cytoskeleton (72,73). Consistent with the important role of these proteins and other RUNX2 responsive genes in cell adhesion and motility, knock-down of RUNX2, TLN1 or PTK2/FAK alters motility of U2OS cells. Because RUNX2 depletion only minimally affects the mRNA levels of either TLN1 or PTK2 (presumably because these genes are very tightly bound by RUNX2), the observed effects of RUNX2 on cell motility

reflect broader involvement of RUNX2 in regulating expression programs supporting cellular movement.

In summary, RUNX2 interacts with the promoters of a cohort of motility genes in SAOS-2 cells. These interactions are not sufficient to generate a mobile cell phenotype, because SAOS-2 cells are not particularly motile. Depletion of RUNX2, TLN1 and PTK2 affects motility of U2OS but not SAOS-2 cells. These findings indicate that RUNX2 is important for movement, but this effect clearly differs among osteosarcoma cell lines and thus depends on biological context. Finally, while the focal adhesion-related RUNX2 target genes TLN1 and PTK2 control cell movement in U2OS cells, RUNX2 becomes rate-limiting at levels that do not yet affect TLN1 or PTK2 gene expression. Therefore, it appears that RUNX2 can control cell movement through alternate molecular pathways, perhaps independent of TLN1 or PTK2. We conclude that elevation of RUNX2 levels in osteosarcoma cells supports its binding to diverse gene loci, which may be linked to the pathology of this pediatric bone cancer.

REFERENCES

1. Wang, C. Q., Jacob, B., Nah, G. S., and Osato, M. (2010) *Blood Cells Mol. Dis.* **44,** 275-286

2. Niebuhr, B., Fischer, M., Tager, M., Cammenga, J., and Stocking, C. (2008) *Blood Cells Mol. Dis.* **40,** 211-218

3. Lian, J. B., Stein, G. S., Javed, A., van Wijnen, A. J., Stein, J. L., Montecino, M., Hassan, M. Q., Gaur, T., Lengner, C. J., and Young, D. W. (2006) *Rev. Endocr. Metab Disord.* **7,** 1-16

4. Chuang, L. S. and Ito, Y. (2010) *Oncogene* **29,** 2605-2615

5. Subramaniam, M. M., Chan, J. Y., Yeoh, K. G., Quek, T., Ito, K., and Salto-Tellez, M. (2009) *Biochim. Biophys. Acta* **1796,** 315-331

6. Kilbey, A., Terry, A., Cameron, E. R., and Neil, J. C. (2008) *Cell Cycle* **7,** 2333-2340

7. Pratap, J., Lian, J. B., Javed, A., Barnes, G. L., van Wijnen, A. J., Stein, J. L., and Stein, G. S. (2006) *Cancer Metastasis Rev.* **25,** 589-600

8. Blyth, K., Cameron, E. R., and Neil, J. C. (2005) *Nat. Rev. Cancer* **5,** 376-387

9. Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., and Downing, J. R. (1996) *Cell* **84,** 321-330

10. Wang, Q., Stacy, T., Binder, M., Marin-Padilla, M., Sharpe, A. H., and Speck, N. A. (1996) *Proc. Natl. Acad. Sci. U. S. A.* **93,** 3444-3449

11. Dowdy, C. R., Xie, R., Frederick, D., Hussain, S., Zaidi, S. K., Vradii, D., Javed, A., Li, X., Jones, S. N., Lian, J. B., van Wijnen, A. J., Stein, J. L., and Stein, G. S. (2010) *Hum. Mol. Genet.* **19,** 1048-1057

12. Li, Q. L., Ito, K., Sakakura, C., Fukamachi, H., Inoue, K., Chi, X. Z., Lee, K. Y., Nomura, S., Lee, C. W., Han, S. B., Kim, H. M., Kim, W. J., Yamamoto, H., Yamashita, N., Yano, T., Ikeda, T., Itohara, S., Inazawa, J., Abe, T., Hagiwara, A., Yamagishi, H., Ooe, A., Kaneda, A., Sugimura, T., Ushijima, T., Bae, S. C., and Ito, Y. (2002) *Cell* **109,** 113-124

13. Inoue, K., Ozaki, S., Shiga, T., Ito, K., Masuda, T., Okado, N., Iseda, T., Kawaguchi, S., Ogawa, M., Bae, S. C., Yamashita, N., Itohara, S., Kudo, N., and Ito, Y. (2002) *Nat. Neurosci.* **5,** 946-954

14. Woolf, E., Xiao, C., Fainaru, O., Lotem, J., Rosen, D., Negreanu, V., Bernstein, Y., Goldenberg, D., Brenner, O., Berke, G., Levanon, D., and Groner, Y. (2003) *Proc. Natl. Acad. Sci. U. S. A* **100,** 7731-7736

15. Stewart, M., Terry, A., O'Hara, M., Cameron, E., Onions, D., and Neil, J. C. (1996) *J. Gen. Virol.* **77 (Pt 3),** 443-446

16. Stewart, M., Terry, A., Hu, M., O'Hara, M., Blyth, K., Baxter, E., Cameron, E., Onions, D. E., and Neil, J. C. (1997) *Proc. Natl. Acad. Sci. U. S. A* **94,** 8646-8651

17. Vaillant, F., Blyth, K., Andrew, L., Neil, J. C., and Cameron, E. R. (2002) *J. Immunol.* **169,** 2866-2874

18. Blyth, K., Vaillant, F., Hanlon, L., Mackay, N., Bell, M., Jenkins, A., Neil, J. C., and Cameron, E. R. (2006) *Cancer Res.* **66,** 2195-2201

19. Mundlos, S., Otto, F., Mundlos, C., Mulliken, J. B., Aylsworth, A. S., Albright, S., Lindhout, D., Cole, W. G., Henn, W., Knoll, J. H. M., Owen, M. J., Mertelsmann, R., Zabel, B. U., and Olsen, B. R. (1997) *Cell* **89,** 773-779

20. Ott, C. E., Leschik, G., Trotier, F., Brueton, L., Brunner, H. G., Brussel, W., Guillen-Navarro, E., Haase, C., Kohlhase, J., Kotzot, D., Lane, A., Lee-Kirsch, M. A., Morlot, S., Simon, M. E., Steichen-Gersdorf, E., Tegay, D. H., Peters, H., Mundlos, S., and Klopocki, E. (2010) *Hum. Mutat.* **31,** E1587-E1593

21. Han, M. S., Kim, H. J., Wee, H. J., Lim, K. E., Park, N. R., Bae, S. C., van Wijnen, A. J., Stein, J. L., Lian, J. B., Stein, G. S., and Choi, J. Y. (2010) *J. Cell Biochem.* **110,** 97-103

22. Kim, H. J., Nam, S. H., Kim, H. J., Park, H. S., Ryoo, H. M., Kim, S. Y., Cho, T. J., Kim, S. G., Bae, S. C., Kim, I. S., Stein, J. L., van Wijnen, A. J., Stein, G. S., Lian, J. B., and Choi, J. Y. (2006) *J. Cell Physiol* **207,** 114-122

23. Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, R. T., Gao, Y.-H., Inada, M., Sato, M., Okamoto, R., Kitamura, Y., Yoshiki, S., and Kishimoto, T. (1997) *Cell* **89,** 755-764

24. Otto, F., Thornell, A. P., Crompton, T., Denzel, A., Gilmour, K. C., Rosewell, I. R., Stamp, G. W. H., Beddington, R. S. P., Mundlos, S., Olsen, B. R., Selby, P. B., and Owen, M. J. (1997) *Cell* **89,** 765-771

25. Choi, J.-Y., Pratap, J., Javed, A., Zaidi, S. K., Xing, L., Balint, E., Dalamangas, S., Boyce, B., van Wijnen, A. J., Lian, J. B., Stein, J. L., Jones, S. N., and Stein, G. S. (2001) *Proc. Natl. Acad. Sci. , USA* **98,** 8650-8655

26. Lou, Y., Javed, A., Hussain, S., Colby, J., Frederick, D., Pratap, J., Xie, R., Gaur, T., van Wijnen, A. J., Jones, S. N., Stein, G. S., Lian, J. B., and Stein, J. L. (2009) *Hum. Mol. Genet.* **18,** 556-568

27. Pratap, J., Galindo, M., Zaidi, S. K., Vradii, D., Bhat, B. M., Robinson, J. A., Choi, J.-Y., Komori, T., Stein, J. L., Lian, J. B., Stein, G. S., and van Wijnen, A. J. (2003) *Cancer Res.* **63,** 5357-5362

28. Galindo, M., Pratap, J., Young, D. W., Hovhannisyan, H., Im, H. J., Choi, J. Y., Lian, J. B., Stein, J. L., Stein, G. S., and van Wijnen, A. J. (2005) *J. Biol. Chem.* **280,** 20274-20285

29. Young, D. W., Hassan, M. Q., Pratap, J., Galindo, M., Zaidi, S. K., Lee, S. H., Yang, X., Xie, R., Javed, A., Underwood, J. M., Furcinitti, P., Imbalzano, A. N., Penman, S., Nickerson, J. A., Montecino, M. A., Lian, J. B., Stein, J. L., van Wijnen, A. J., and Stein, G. S. (2007) *Nature* **445,** 442-446

30. Zaidi, S. K., Pande, S., Pratap, J., Gaur, T., Grigoriu, S., Ali, S. A., Stein, J. L., Lian, J. B., van Wijnen, A. J., and Stein, G. S. (2007) *Proc. Natl. Acad. Sci. U. S. A* **104,** 19861-19866

31. Teplyuk, N. M., Galindo, M., Teplyuk, V. I., Pratap, J., Young, D. W., Lapointe, D., Javed, A., Stein, J. L., Lian, J. B., Stein, G. S., and van Wijnen, A. J. (2008) *J. Biol. Chem.* **283,** 27585-27597

32. Kilbey, A., Blyth, K., Wotton, S., Terry, A., Jenkins, A., Bell, M., Hanlon, L., Cameron, E. R., and Neil, J. C. (2007) *Cancer Res.* **67,** 11263-11271

33. Galindo, M., Kahler, R. A., Teplyuk, N. M., Stein, J. L., Lian, J. B., Stein, G. S., Westendorf, J. J., and van Wijnen, A. J. (2007) *J. Mol. Histol.* **38,** 501-506

34. San Martin, I. A., Varela, N., Gaete, M., Villegas, K., Osorio, M., Tapia, J. C., Antonelli, J., Mancilla, E., Pereira, B. P., Nathan, S. S., Lian, J. B., Stein, J. L., Stein, G. S., van Wijnen, A. J., and Galindo, M. (2009) *J. Cell. Physiol.* **221,** 560-571

35. Pereira, B. P., Zhou, Y., Gupta, A., Leong, D. T., Aung, K. Z., Ling, L., Pho, R. W., Galindo, M., Salto-Tellez, M., Stein, G. S., Cool, S. M., van Wijnen, A. J., and Nathan, S. S. (2009) *J. Cell. Physiol.* **221,** 778-788

36. Sadikovic, B., Thorner, P., Chilton-MacNeill, S., Martin, J. W., Cervigne, N. K., Squire, J., and Zielenska, M. (2010) *BMC. Cancer* **10,** 202

37. Martin, J. W., Yoshimoto, M., Ludkovski, O., Thorner, P. S., Zielenska, M., Squire, J. A., and Nuin, P. A. (2010) *Cytogenet. Genome Res.* **128,** 199-213

38. Teplyuk, N. M., Zhang, Y., Lou, Y., Hawse, J. R., Hassan, M. Q., Teplyuk, V. I., Pratap, J., Galindo, M., Stein, J. L., Stein, G. S., Lian, J. B., and van Wijnen, A. J. (2009) *Mol. Endocrinol.* **23,** 849-861

39. Jeong, J. H., Jung, Y. K., Kim, H. J., Jin, J. S., Kim, H. N., Kang, S. M., Kim, S. Y., van Wijnen, A. J., Stein, J. L., Lian, J. B., Stein, G. S., Kato, S., and Choi, J. Y. (2010) *Mol. Cell Biol.* **30,** 2365-2375

40. Young, D. W., Hassan, M. Q., Yang, X.-Q., Galindo, M., Javed, A., Zaidi, S. K., Furcinitti, P., Lapointe, D., Montecino, M., Lian, J. B., Stein, J. L., van Wijnen, A. J., and Stein, G. S. (2007) *Proc. Natl. Acad. Sci. USA* **104,** 3189-3194

41. Westendorf, J. J., Zaidi, S. K., Cascino, J. E., Kahler, R., van Wijnen, A. J., Lian, J. B., Yoshida, M., Stein, G. S., and Li, X. (2002) *Mol. Cell Biol.* **22,** 7982-7992

42. Jensen, E. D., Niu, L., Caretti, G., Nicol, S. M., Teplyuk, N., Stein, G. S., Sartorelli, V., van Wijnen, A. J., Fuller-Pace, F. V., and Westendorf, J. J. (2008) *J. Cell Biochem.* **103,** 1438-1451

43. Teplyuk, N. M., Haupt, L. M., Ling, L., Dombrowski, C., Mun, F. K., Nathan, S. S., Lian, J. B., Stein, J. L., Stein, G. S., Cool, S. M., and van Wijnen, A. J. (2009) *J. Cell Biochem.* **107,** 144-154

44. Haupt, L. M., Murali, S., Mun, F. K., Teplyuk, N., Mei, L. F., Stein, G. S., van Wijnen, A. J., Nurcombe, V., and Cool, S. M. (2009) *J. Cell Physiol* **220,** 780-791

45. Akech, J., Wixted, J. J., Bedard, K., van der Deen, M., Hussain, S., Guise, T. A., van Wijnen, A., Stein, J. L., Languino, L. R., Altieri, D. C., Pratap, J., Keller, E., Stein, G. S., and Lian, J. B. (2010) *Oncogene* **29,** 811-821

46. Pratap, J., Imbalzano, K., Underwood, J., Cohet, N., Gokul, K. D., Akech, J., van Wijnen, A. J., Stein, J. L., Imbalzano, A. N., Nickerson, J. A., Lian, J. B., and Stein, G. S. (2009) *Cancer Res* **69,** 6807-6814

47. Pratap, J., Wixted, J. J., Gaur, T., Zaidi, S. K., Dobson, J., Gokul, K. D., Hussain, S., van Wijnen, A. J., Stein, J. L., Stein, G. S., and Lian, J. B. (2008) *Cancer Res.* **68,** 7795-7802

48. Baniwal, S. K., Khalid, O., Gabet, Y., Shah, R. R., Purcell, D. J., Mav, D., Kohn-Gabet, A. E., Shi, Y., Coetzee, G. A., and Frenkel, B. (2010) *Mol. Cancer* **9,** 258

49. Pregizer, S., Barski, A., Gersbach, C. A., Garcia, A. J., and Frenkel, B. (2007) *J. Cell Biochem.* **102,** 1458-1471

50. Thirunavukkarasu, K., Pei, Y., and Wei, T. (2007) *Mol. Biol. Rep.* **34,** 225-231

51. Thirunavukkarasu, K., Pei, Y., Moore, T. L., Wei, T., Wang, H., and Chandrasekhar, S. (2007) *Mol. Biol. Rep.* **34,** 1-10

52. Kilbey, A., Terry, A., Jenkins, A., Borland, G., Zhang, Q., Wakelam, M. J., Cameron, E. R., and Neil, J. C. (2010) *Cancer Res.* **70,** 5860-5869

53. Lee, T. I., Johnstone, S. E., and Young, R. A. (2006) *Nat. Protoc.* **1,** 729-748

54. van der Deen, M., Hassan, M. Q., Pratap, J., Teplyuk, N. M., Young, D. W., Javed, A., Zaidi, S. K., Lian, J. B., Montecino, M., Stein, J. L., Stein, G. S., and van Wijnen, A. J. (2008) *Methods Mol. Biol.* **455,** 165-176

55. O'Geen, H., Nicolet, C. M., Blahnik, K., Green, R., and Farnham, P. J. (2006) *Biotechniques* **41,** 577-580

56. Drissi, H., Pouliot, A., Stein, J. L., van Wijnen, A. J., Stein, G. S., and Lian, J. B. (2002) *J. Cell Biochem.* **86,** 403-412

57. Frith, M. C., Fu, Y., Yu, L., Chen, J. F., Hansen, U., and Weng, Z. (2004) *Nucleic Acids Res.* **32,** 1372-1381

58. McLeay, R. C. and Bailey, T. L. (2010) *BMC. Bioinformatics.* **11,** 165

59. Vlieghe, D., Sandelin, A., De Bleser, P. J., Vleminckx, K., Wasserman, W. W., van, R. F., and Lenhard, B. (2006) *Nucleic Acids Res.* **34,** D95-D97

60. Sandelin, A., Alkema, W., Engstrom, P., Wasserman, W. W., and Lenhard, B. (2004) *Nucleic Acids Res.* **32,** D91-D94

61. Knuppel, R., Dietze, P., Lehnberg, W., Frech, K., and Wingender, E. (1994) *J. Comput. Biol.* **1,** 191-198

62. Li, C. and Wong, W. H. (2001) *Proc. Natl. Acad. Sci. U. S. A* **98,** 31-36

63. Balint, E., Lapointe, D., Drissi, H., van der Meijden, C., Young, D. W., van Wijnen, A. J., Stein, J. L., Stein, G. S., and Lian, J. B. (2003) *J. Cell. Biochem.* **89,** 401-426

64. van der Meijden, C. M., Lapointe, D. S., Luong, M. X., Peric-Hupkes, D., Cho, B., Stein, J. L., van Wijnen, A. J., and Stein, G. S. (2002) *Cancer Res.* **62,** 3233-3243

65. Ruijter, J. M., Ramakers, C., Hoogaars, W. M., Karlen, Y., Bakker, O., van den Hoff, M. J., and Moorman, A. F. (2009) *Nucleic Acids Res.* **37,** e45

66. Drissi, H., Luc, Q., Shakoori, R., Chuva de Sousa Lopes, S., Choi, J.-Y., Terry, A., Hu, M., Jones, S., Neil, J. C., Lian, J. B., Stein, J. L., van Wijnen, A. J., and Stein, G. S. (2000) *J. Cell. Physiol.* **184,** 341-350

67. Rodan, G. A. and Noda, M. (1991) *Crit Rev. Eukaryot. Gene Expr.* **1,** 85-98

68. Meyers, S., Downing, J. R., and Hiebert, S. W. (1993) *Mol. Cell. Biol.* **13,** 6336-6345

69. Otto, F., Lubbert, M., and Stock, M. (2003) *J Cell Biochem.* **89,** 9-18

70. Huang, d. W., Sherman, B. T., and Lempicki, R. A. (2009) *Nat. Protoc.* **4,** 44-57

71. Wang, C., Fu, M., Mani, S., Wadler, S., Senderowicz, A. M., and Pestell, R. G. (2001) *Front Biosci.* **6,** D610-D629

72. Shattil, S. J., Kim, C., and Ginsberg, M. H. (2010) *Nat. Rev. Mol. Cell Biol.* **11,** 288-300

73. Moser, M., Legate, K. R., Zent, R., and Fassler, R. (2009) *Science* **324,** 895-899

74. Pratap, J., Javed, A., Languino, L. R., van Wijnen, A. J., Stein, J. L., Stein, G. S., and Lian, J. B. (2005) *Mol. Cell. Biol.* **25,** 8581-8591

75. Leong, D. T., Lim, J., Goh, X., Pratap, J., Pereira, B. P., Kwok, H. S., Nathan, S. S., Dobson, J. R., Lian, J. B., Ito, Y., Voorhoeve, P. M., Stein, G. S., Salto-Tellez, M., Cool, S. M., and van Wijnen, A. J. (2010) *Breast Cancer Res.* **12,** R89

76. Das, K., Leong, D. T., Gupta, A., Shen, L., Putti, T., Stein, G. S., van Wijnen, A. J., and Salto-Tellez, M. (2009) *Eur. J. Cancer* **45,** 2239-2248

77. Pratap, J., Lian, J. B., and Stein, G. S. (2010) *Bone* **48,** 30-36

78. van der Deen, M., Akech, J., Wang, T., FitzGerald, T. J., Altieri, D. C., Languino, L. R., Lian, J. B., van Wijnen, A. J., Stein, J. L., and Stein, G. S. (2010) *J. Cell. Biochem.* **109,** 828-837

79. Farnham, P. J. (2009) *Nat. Rev. Genet.* **10,** 605-616

FOOTNOTES

We thank Srivatsan Padmanabhan, Sandhya Pande, Viktor Teplyuk, Nadiya Teplyuk, Jitesh Pratap, S. Kaleem Zaidi, Mei Xu, Akhter Ali and Mohammad Hassan for stimulating discussions. We also thank Charlene Baron for digital imaging advice, Judy Rask for assistance with manuscript preparation, as well as Phyllis Spatrick from the UMass Genomics Core for assistance with Affymetrix analysis. This work is supported in part by grants from NIH: AR49069, CA082834 and AR048818. The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.

FIGURE LEGENDS

Figure 1. RUNX2 and RNAPII ChIP-on-chip. **A.** Average occupancy by RUNX2 and RNAPII is shown from two independent original ChIP samples with ChIP-qPCR. **B.** Total number of genes with RUNX2

and RNAPII promoter occupancy in two independent ChIP samples. 1550 Gene targets were both bound by RUNX2 and RNAPII.

Figure 2. RUNX2 occupancy in promoter regions identified with ChIP-on-chip experiments. **A.** In two independent experiments (n=1 and n=2), RUNX2 enrichment is high on its own P1 promoter, as well as on the shared TLN1-CREB3 promoter region. Enrichment is relatively low on the known RUNX2 target gene MMP13, and there is no significant enrichment on BGLAP (osteocalcin) which is not expressed in SAOS-2 cells. **B.** Validation of RUNX2 targets with ChIP-qPCR. Averages are shown from two independent ChIP samples. Primers were designed around Runx motifs observed in peak regions identified in Panel A (see Table S1 for exact locations within the peak). The fold-enrichment observed in Panels A and B are not directly comparable because the tiles in the Nimblegen promoter array do not match the amplicons of the qPCR primers.

Figure 3. Average distance of RUNX2 and RNAPII binding relative to the transcription start site (TSS) and RUNX2 Motif analysis. **A.** The frequency of RUNX2 binding is maximal at ~800bp upstream of the TSS on average, and relatively low at the TSS. When RNAPII positive promoters are included (left and middle panel), there is an enrichment in RUNX2 binding at ~300 bp downstream of the TSS, which is absent in promoters of genes that are RNAPII negative. The average RNAPII binding is proximal to the maximal average RUNX2 binding. **B.** A RUNX2 motif was generated from the consensus motif present in all peak regions that aligned in duplicate experiments. The motif was generated with weblogo.berkeley.edu. **C.** Frequency of detected Runx Motifs in peak regions of genes in relation to co-occupancy with RNA polymerase II. **D.** Summary of specific Runx binding motifs and their occurrence in peak regions (left columns), or a 500 bp interval (+/- 250 bp) centered on the peak region (right columns).

Figure 4. RUNX2 regulates genes that play a role in cell motility. RUNX2 knockdown with two different siRunx2 oligonucleotides (48 h) in SAOS-2, U2OS and MDA-MB-231 cells affects several genes that are involved in motility and adhesion of cells as identified with ChIP-on-chip. The bar graphs (middle panels) show average effects of the two different siRNA oligos compared to two negative non-silencing RNAs on gene expression as measured by RT-qPCR. The errors in technical replicates within the same biological sample were negligible and not indicated. Black and grey bars indicate effects of more than 30%; white bars indicate no significant effects; Ø: no expression. RUNX2 knockdown at the protein level (left panels) is shown by Western blot analysis using lysates from SAOS-2, U2OS and MDA-MB-231 cells treated with or without siRUNX2. Western blots were quantified using ImageJ (http:// imagej.nih.gov/ij/ index.html) and revealed a >70% reduction in RUNX2 levels in all cell lines.

Figure 5. RUNX2 target genes that play a role in cell motility and adhesion as identified using a qPCR-array. **A.** A qPCR array was developed for ~50 different genes. The genes that showed more than 20% up- or downregulation (on average) are displayed in this graph. RUNX2 knockdown (48 h) in SAOS-2 cells affects several genes that are involved in cell motility and adhesion. Averages are shown from two different siRunx2 oligonucleotides versus the average of mock transfection and non-silencing RNA. Expression levels were analyzed using a qPCR array with GAPDH as internal control. Black bars, negative controls; dark grey bar, RUNX2 downregulation; light grey bars, new potential target genes that are affected more than 20% (indicated with dotted lines) compared to GAPDH upon treatment with siRUNX2 ('smart pool') oligos. **B.** RUNX2 occupancy on gene promoters of a selection of genes that are siRNA responsive. Occupancy of independent duplicate experiments are shown (n=1 and n=2). Significant peak regions are shown in different shades of gray, based on level of significance.

Figure 6. RUNX2 downregulation inhibits motility of U2OS osteosarcoma cells. **A.** Diagram showing the transcriptional regulation of two proteins (PTK2/FAK and TLN) that function together at focal adhesions at the cell surface. **B.** RT-qPCR analysis of RUNX2, PTK2 and TLN1 knockdown by siRNA (48 h) in U2OS cells, non-silencing siRNA (NS) was used as control. Error bars represent SD values of

triplicate measurements. **C**. Depletion of RUNX2 and two representative target genes delays migration of U2OS cells in wound healing assays. Cell migration was analyzed by phase contrast microscopy over a 24 h time course. Representative images of wound healing at 0 h and 24 h after scratch are presented. **D**. The difference in cell migration and wound healing was quantified as the percentage of wound healing compared to control siRNA. Wound healing was quantified using ImageJ (http:// rsbweb.nih.gov/ ij/). Values represent averages (± SD) of three independent measurements along the wound scratch. Data are representative of three independent experiments. **E**. Invasion of U2OS cells is impaired when RUNX2 is downregulated (48 h) in a transwell culture assay with different oligos siRUNX2-A, and -B. Right panels: RUNX2 downregulation at the protein level. Graphs depict the number of invaded cells as a percentage of the migrated cells, based on four separate cell counts that covered almost the entire well. The averages and SD values of these cell counts show only minimal technical variation and are not shown. Biological variation is evidenced by the values obtained for two different siRNAs for specific depletion of Runx2 (siRUNX2-A and -B) and two negative non-silencing controls (siNS-A and siNS-B). One of two representative experiments with similar results is shown.

Figure 1

A


Fold enrichment
10
9
8
7
6
5
4
3
2
1
0
Runx2
IgG
450
400
350
300
250
200
150
100
50
0
RNAPII
IgG
Runx2 promoter ChIP-qPCR (original ChIP)

B


Runx2
RNAPII
789
1550
5109
Total gene targets (ChIP-on-chip)

Figure 2

A


45,400,000
45,401,000
45,402,000
45,403,000
45,404,000
45,405,000
35,718,000
35,719,000
35,720,000
35,721,000
35,722,000
35,723,000
35,724,000
35,725,000
102,330,000
102,331,000
102,332,000
102,333,000
102,334,000
154,474,000
154,475,000
154,476,000
154,477,000
154,478,000
154,479,000
154,480,000
RUNX2 ChIP
n=1
n=2
RNAPII ChIP
n=1
n=2
Gene transcripts
RUNX2 P1
TLN1
CREB3
MMP13
BGLAP (osteocalcin)

B


Fold enrichment over input
0
5
10
15
20
25
30
35
40
45
RUNX1
SCT/ MUCDHL
RUNX2
C10orf4
SERPINE1
TLN1/ CREB3
PTK2
HIST1H2AB/ HIST1H3B
KBTBD6
SLC7A10
CCDC97
CDKN1A
Input

Figure 3

A





B



C

	Runx2-all peaks	Runx2/RNAPII	Runx2/noRNAPII
Genes with Runx2 occupancy	2339	1550	789
Genes + Runx Motifs in peak region	1484 (63%)	978 (63%)	509 (65%)
Genes + Runx Motifs in peak region +/- 250bp	1940 (83%)	1251 (81%)	692 (88%)

D

	Runx2-all peaks		Runx2/RNAPII		Runx2/noRNAPII	
Runx Motif	peak region	peak region	peak region	peak region	peak region	peak region
[TAC]G[CT]GGT		+/-250bp		+/-250bp		+/-250bp
TGTGGT	883	1889	542	1113	342	718
TGTGGG	762	1689	505	1106	261	587
TGAGGT	538	1302	358	867	180	441
AGTGGT	493	1160	307	708	187	454
TGCGGT	196	488	117	297	79	192
CGTGGT	163	438	113	309	50	130
AGCGGT	104	284	79	219	25	65
CGCGGT	50	245	40	201	10	44

Figure 4


Relative mRNA
RUNX1
CDKN1A
RUNX2
MMP13
COL11A1
TLN1
FLRT2
SERPINE1
NEXN
PTK2
SHC1
TPM1
KBTBD6
ITGB3BP
MTA3
CREB3
LUM
FNDC6
Relative mRNA
RUNX1
CDKN1A
MMP13
RUNX2
NEXN
FLRT2
COL11A1
SERPINE1
TPM1
CREB3
TLN1
SHC1
PTK2
ITGB3BP
KBTBD6
MTA3
LUM
FNDC6
Relative mRNA
RUNX1
CDKN1A
RUNX2
MMP13
FLRT2
SERPINE1
SHC1
NEXN
ITGB3BP
CREB3
TLN1
PTK2
KBTBD6
TPM1
MTA3
COL11A1
LUM
FNDC6


SAOS-2
Mock
siRunx2-A
siNS-B
siRunx2-B
Runx2
CDK2


U2OS
siNS-A
siRunx2-A
siNS-B
siRunx2-B
Runx2
CDK2


MDA-MB-231
Mock
siRunx2-A
siNS-B
siRunx2-B
Runx2
CDK2

Figure 5

A


Relative mRNA
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
GAPDH
MCOX
Runx2
PCDH18
ISL1
CSNK2B
NUDT12
HAPLN1
SVIL
PANX3
COL24A1

B


138,672,000
138,673,000
138,674,000
138,675,000
123,983,000
123,984,000
123,985,000
123,986,000
123,987,000
123,988,000
29,963,000
29,964,000
29,965,000
29,966,000
86,393,000
86,394,000
86,395,000
86,396,000
86,397,000
50,712,000
50,713,000
50,714,000
50,715,000
PCDH18
PANX3
SVIL
COL24A1
ISL1

Figure 6